counting, and number of agents. Univariate analysis was conducted with each potential factor to determine an association between that factor and drop-out. The association was also tested after controlling for the number of daily doses. Multivariate analysis, using logistic regression, was used to determine the effect of each factor after controlling for all others. A probability of 0.05 or less was accepted as statistically significant and the Bonferroni correction was used for multiple analysis. Publication bias was assessed using a funnel plot.
How were differences between studies investigated? Heterogeneity was tested using the Q statistic.
Results of the review
Sixty-three studies were included (5996 patients).
Association of various factors:
Influence of number of drugs in regime.
Regimes containing three or more agents had higher drop-out rates in univariate analysis than those with one of two (P = 0.039). After controlling for all other characteristics, regimes with more than two drugs had a lower drop-out rate (P = 0.0124).
There was no statistical significance in drop-out rates due to adverse effects based on the number of agents in a regime.
The number of drugs in the regime had a significant impact on drop-out rates due to noncompliance in univariate analysis (P = 0.001). After controlling for number of doses per day, the drop-out rate was significantly lower with regimes of three or more agents compared with those of one or two (P = 0.0001).
Influence of the number of doses per day.
Regimes containing three or fewer doses/day had a lower drop-out rate than regimes with 4 to 6 doses/day (P = 0.001), 7 to 11 doses/day (P = 0.009) or 12 or more (P < 0.0001). Rates were similar in regimes with 4 to 6 and 7 to 11 doses/day. Patients taking 7 to 11 doses/day were less likely to drop-out than those taking 12 or more (P = 0.0018).
After controlling for the number of doses/day, drug regimes with adverse reaction counselling (P = 0.0001), short duration of therapy (P = 0.0110), and fewer agents (P = 0.0322) had higher drop-out rates.
After controlling for other factors, regimes with a proton pump inhibitor (P = 0.0343), and compliance counselling (P = 0.0322) had lower rates.
Drop-out due to adverse effects.
After controlling for the number of doses/day, regimes with bismuth (P = 0.0001), and ADR documentation (P = 0.0080) had significantly high drop-out rates due to adverse reactions and those with a proton pump inhibitor has significantly low rates (P = 0.0168).
Multivariate analysis controlling for all other factors, showed higher drop-out rates for regimes with bismuth and ADR documentation.
Drop-out due to noncompliance.
Multivariate analysis showed no changes in drop-outs due to noncompliance.
Heterogeneity and publication bias.
There was no evidence of heterogeneity for total drop-outs (Q = 26.46, P = 0.99), drop-outs due to side-effects (Q = 7.68, P = 0.94), or those due to noncompliance (Q = 2.92, P = 0.89).
